Company Overview
Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland.
Similarly Why is Aurinia Pharmaceuticals a buy? Investors and analysts rating Aurinia Pharmaceuticals a Buy are doing so based on its late-stage positioning in LN treatment. The FDA’s NDA fast-track approval shortens the research window to under 12 months, which means we’ll know by the end of 2021 whether the treatment works.
How many employees does Aurinia? Compare AUPH With Other Stocks
| Aurinia Pharmaceuticals Inc Annual Number of Employees | |
|---|---|
| 2020 | 294 |
| 2019 | 62 |
| 2018 | 39 |
| 2017 | 33 |
Additionally, What is the target price for BCRX stock?
Stock Price Targets
| High | $30.00 |
|---|---|
| Median | $17.50 |
| Low | $14.00 |
| Average | $19.50 |
| Current Price | $12.59 |
il y a 4 jours
Is Bcrx a buy right now?
BioCryst Pharmaceuticals has received a consensus rating of Buy.
Will BCRX go up? The 12 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 17.50, with a high estimate of 30.00 and a low estimate of 14.00. The median estimate represents a +53.64% increase from the last price of 11.39.
Is BCRX stock a good buy? Out of 6 analysts, 2 (33.33%) are recommending BCRX as a Strong Buy, 2 (33.33%) are recommending BCRX as a Buy, 2 (33.33%) are recommending BCRX as a Hold, 0 (0%) are recommending BCRX as a Sell, and 0 (0%) are recommending BCRX as a Strong Sell. What is BCRX’s earnings growth forecast for 2022-2024?
Why is BioCryst going up? The big gain came after the company provided an upbeat update on Monday. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. This figure brings the full-year 2021 sales for the drug to $122 million.
Why is BCRX dropping?
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were crashing 32.9% lower as of 10:38 a.m. ET on Friday. The steep decline came after the company announced that it has paused enrollment in three clinical studies evaluating experimental drug BCX9930.
Is BioCryst a good company? BioCryst Pharmaceuticals has an overall rating of 3.9 out of 5, based on over 10 reviews left anonymously by employees. 65% of employees would recommend working at BioCryst Pharmaceuticals to a friend and 62% have a positive outlook for the business.
When did BCRX go public?
When was BioCryst founded and when did the company go public? BioCryst was founded in 1986 and completed its Initial Public Offering in March 1994. The Company’s stock is traded on the NASDAQ exchange under the symbol BCRX.
How many employees does BioCryst have? BioCryst Pharmaceuticals
| Type | Public |
|---|---|
| Key people | Jon P. Stonehouse , President and Chief Executive Officer |
| Products | RABIVAP |
| Revenue | $49 Million(2019) |
| Number of employees | 110 |
What does BioCryst make?
About BioCryst Pharmaceuticals, Inc.
(BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease.
Who owns BioCryst Pharmaceuticals?
State Street Global Advisors, Inc. is currently the largest shareholder, with 10% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 9.0% of common stock, and Baker Bros. Advisors LP holds about 7.2% of the company stock.
Where is BioCryst located? BioCryst’s US headquarters is located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama.
What is BioCryst Pharmaceuticals working on? BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg …
What does BioCryst Pharma do?
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
How many shares does BioCryst have? BioCryst Pharmaceuticals, Inc. (US:BCRX) has 429 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 134,860,198 shares. Largest shareholders include BlackRock Inc., Baker Bros.